Summary & Overview
CPT 0503U: PrecivityAD2 Blood Beta‑Amyloid and Tau Assay
CPT code 0503U designates a Proprietary Laboratory Analyses (PLA) test for PrecivityAD2™ developed by C2N Diagnostics LLC. The assay quantifies beta amyloid and tau proteins in blood using immunoprecipitation and LC–MS/MS and produces an algorithmic score estimating likelihood of amyloid plaques associated with Alzheimer disease. This PLA code is unique to the single manufacturer and test, which has implications for coverage, billing specificity, and laboratory reporting.
Key national payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes how payers treat PLA-designated tests, typical billing practices for proprietary assays, and payer-specific considerations that influence access and reimbursement nationally.
Readers will find a concise explanation of the clinical context for blood-based Alzheimer biomarkers, benchmarking of common payer coverage approaches, a summary of coding and billing considerations tied to PLA status, and implications for clinical laboratories and ordering clinicians. The report highlights service settings where this test is delivered, common billing modifiers used with laboratory services (input list provided), and notes limitations where input data were not supplied.
Billing Code Overview
CPT code 0503U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to a single commercially available laboratory test. Report 0503U only for PrecivityAD2™ from C2N Diagnostics LLC. The test uses immunoprecipitation and liquid chromatography with tandem mass spectrometry (LC–MS/MS) to measure beta amyloid and tau–protein levels in blood and generates an algorithm score estimating the likelihood of amyloid plaque associated with Alzheimer disease.
-
Service type: Proprietary laboratory diagnostic assay providing a quantitative algorithmic blood biomarker score for Alzheimer disease risk assessment
-
Typical site of service: Clinical laboratory or outpatient phlebotomy collection site
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with progressive memory decline is referred by a neurologist for blood-based biomarker testing to assess the likelihood of cerebral amyloid plaque deposition. The clinician documents mild cognitive impairment versus early Alzheimer disease in the history of present illness and orders the proprietary PrecivityAD2™ test to measure plasma beta-amyloid and tau proteins using immunoprecipitation and liquid chromatography–tandem mass spectrometry (LC–MS/MS). A phlebotomy is scheduled at an outpatient laboratory or hospital draw station; the specimen is sent to C2N Diagnostics LLC for analysis. Results provide an algorithm-derived score indicating the probability of amyloid plaque presence, which the ordering clinician integrates with clinical assessment, neuroimaging, and neuropsychological testing to inform diagnostic discussions and care planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; standard reporting | Use when no modifier applies to the laboratory service. |
| 26 | Professional component | Use when reporting only the professional interpretation component if applicable (rare for PLA codes; applies when separate professional interpretation is billed).
| 52 | Reduced services | Use when the test is partially performed or limited in scope compared with the full service.